PH12017500710B1 - Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists - Google Patents
Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonistsInfo
- Publication number
- PH12017500710B1 PH12017500710B1 PH1/2017/500710A PH12017500710A PH12017500710B1 PH 12017500710 B1 PH12017500710 B1 PH 12017500710B1 PH 12017500710 A PH12017500710 A PH 12017500710A PH 12017500710 B1 PH12017500710 B1 PH 12017500710B1
- Authority
- PH
- Philippines
- Prior art keywords
- liver disease
- fatty liver
- glucocorticoid
- receptor antagonists
- disease treatment
- Prior art date
Links
- 208000010706 fatty liver disease Diseases 0.000 title abstract 2
- 229940083712 aldosterone antagonist Drugs 0.000 title 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 title 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462064358P | 2014-10-15 | 2014-10-15 | |
| US201462092041P | 2014-12-15 | 2014-12-15 | |
| PCT/US2015/055487 WO2016061195A1 (en) | 2014-10-15 | 2015-10-14 | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12017500710A1 PH12017500710A1 (en) | 2017-10-09 |
| PH12017500710B1 true PH12017500710B1 (en) | 2024-01-17 |
Family
ID=55747256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2017/500710A PH12017500710B1 (en) | 2014-10-15 | 2015-10-14 | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10238659B2 (enExample) |
| EP (3) | EP4792880A2 (enExample) |
| JP (1) | JP6761410B2 (enExample) |
| KR (1) | KR102435956B1 (enExample) |
| CN (2) | CN107106562B (enExample) |
| AU (1) | AU2015333645B2 (enExample) |
| BR (1) | BR112017007860B1 (enExample) |
| CA (1) | CA2964625C (enExample) |
| DK (2) | DK4353310T3 (enExample) |
| ES (1) | ES2978871T3 (enExample) |
| FI (2) | FI4353310T3 (enExample) |
| IL (1) | IL251729B (enExample) |
| MX (1) | MX2017004943A (enExample) |
| NZ (1) | NZ731060A (enExample) |
| PH (1) | PH12017500710B1 (enExample) |
| PL (1) | PL3206692T3 (enExample) |
| PT (2) | PT4353310T (enExample) |
| RU (1) | RU2718921C2 (enExample) |
| SG (1) | SG11201703024VA (enExample) |
| UA (1) | UA123537C2 (enExample) |
| WO (1) | WO2016061195A1 (enExample) |
| ZA (1) | ZA201702813B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703024VA (en) | 2014-10-15 | 2017-05-30 | Corcept Therapeutics Inc | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
| CA3102099C (en) * | 2018-06-04 | 2023-09-26 | Corcept Therapeutics Incorporated | Pyrimidine cyclohexenyl glucocorticoid receptor modulators |
| AU2020239920A1 (en) | 2019-03-18 | 2021-11-04 | Arnold L. Newman | Method of improving insulin sensitivity |
| KR102911885B1 (ko) | 2020-05-06 | 2026-01-12 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제의 다형체 |
| AU2021266739B2 (en) * | 2020-05-06 | 2024-11-28 | Corcept Therapeutics Incorporated | Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators |
| KR102481705B1 (ko) * | 2020-08-04 | 2022-12-27 | 연세대학교 산학협력단 | 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물 |
| JP7853982B2 (ja) * | 2020-12-21 | 2026-04-30 | コーセプト セラピューティクス， インコーポレイテッド | ピリミジンシクロヘキシルグルココルチコイド受容体調節因子を調製する方法 |
| US12616698B2 (en) | 2021-05-05 | 2026-05-05 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and for treating fatty liver disorders |
| AU2022271209B2 (en) * | 2021-05-05 | 2026-07-02 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and for treating fatty liver disorders |
| WO2025174745A1 (en) * | 2024-02-12 | 2025-08-21 | Corcept Therapeutics Incorporated | MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS |
| WO2025255357A1 (en) * | 2024-06-06 | 2025-12-11 | Corcept Therapeutics Incorporated | Methods for preparing and maintaining livers and portions thereof for liver transplantation |
| EP4732836A1 (en) | 2024-10-22 | 2026-04-29 | Consejo Superior De Investigaciones Científicas | Ag5 compound for use in the treatment of in fatty liver diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2153546A (en) | 1936-07-29 | 1939-04-11 | Universal Draft Gear Attachmen | Hand brake actuating mechanism |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB0213745D0 (en) * | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
| JP2006508042A (ja) | 2002-07-18 | 2006-03-09 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体の修飾物質および方法 |
| EP1883624B1 (en) | 2005-05-18 | 2010-04-07 | Merck Sharp & Dohme Corp. | D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands |
| US8389472B2 (en) * | 2005-08-19 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
| AU2006292293B2 (en) * | 2005-09-19 | 2012-09-13 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
| GB0601092D0 (en) * | 2006-01-19 | 2006-03-01 | Daniolabs Ltd | The Prevention Of Systemic Side-Effects Of Glucocorticoids |
| ES2546181T3 (es) | 2006-05-09 | 2015-09-21 | Genzyme Corporation | Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US20100144764A1 (en) * | 2007-04-13 | 2010-06-10 | Schering Corporation | Pyrimidinedione derivatives and methods of use thereof |
| US8003689B2 (en) | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| CA2738573C (en) | 2009-04-03 | 2013-02-19 | F. Hoffmann-La Roche Ag | Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof |
| CN103596431B (zh) * | 2011-03-18 | 2016-06-22 | 科赛普特治疗公司 | 嘧啶环己基糖皮质激素受体调节剂 |
| SG11201703024VA (en) | 2014-10-15 | 2017-05-30 | Corcept Therapeutics Inc | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
-
2015
- 2015-10-14 SG SG11201703024VA patent/SG11201703024VA/en unknown
- 2015-10-14 FI FIEP24157529.9T patent/FI4353310T3/fi active
- 2015-10-14 PT PT241575299T patent/PT4353310T/pt unknown
- 2015-10-14 CN CN201580068262.4A patent/CN107106562B/zh active Active
- 2015-10-14 DK DK24157529.9T patent/DK4353310T3/da active
- 2015-10-14 MX MX2017004943A patent/MX2017004943A/es active IP Right Grant
- 2015-10-14 FI FIEP15851238.4T patent/FI3206692T3/fi active
- 2015-10-14 EP EP26180646.7A patent/EP4792880A2/en active Pending
- 2015-10-14 NZ NZ731060A patent/NZ731060A/en unknown
- 2015-10-14 PT PT158512384T patent/PT3206692T/pt unknown
- 2015-10-14 ES ES15851238T patent/ES2978871T3/es active Active
- 2015-10-14 KR KR1020177012950A patent/KR102435956B1/ko active Active
- 2015-10-14 EP EP24157529.9A patent/EP4353310B1/en active Active
- 2015-10-14 PH PH1/2017/500710A patent/PH12017500710B1/en unknown
- 2015-10-14 JP JP2017520388A patent/JP6761410B2/ja active Active
- 2015-10-14 EP EP15851238.4A patent/EP3206692B1/en active Active
- 2015-10-14 CA CA2964625A patent/CA2964625C/en active Active
- 2015-10-14 PL PL15851238.4T patent/PL3206692T3/pl unknown
- 2015-10-14 BR BR112017007860-0A patent/BR112017007860B1/pt active IP Right Grant
- 2015-10-14 CN CN202010597452.8A patent/CN111557942B/zh active Active
- 2015-10-14 UA UAA201704069A patent/UA123537C2/uk unknown
- 2015-10-14 AU AU2015333645A patent/AU2015333645B2/en active Active
- 2015-10-14 RU RU2017114596A patent/RU2718921C2/ru active
- 2015-10-14 DK DK15851238.4T patent/DK3206692T3/da active
- 2015-10-14 US US14/883,369 patent/US10238659B2/en active Active
- 2015-10-14 WO PCT/US2015/055487 patent/WO2016061195A1/en not_active Ceased
-
2017
- 2017-04-13 IL IL251729A patent/IL251729B/en active IP Right Grant
- 2017-04-21 ZA ZA2017/02813A patent/ZA201702813B/en unknown
-
2019
- 2019-01-24 US US16/256,295 patent/US10881660B2/en active Active
-
2020
- 2020-12-03 US US17/111,288 patent/US11590135B2/en active Active
-
2023
- 2023-01-26 US US18/101,986 patent/US12226417B2/en active Active
-
2025
- 2025-01-09 US US19/014,779 patent/US20250221995A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015333645B2 (en) | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | |
| CY2025016I2 (el) | Ενωσεις και συνθεσεις για ρυθμιση δραστικοτητων κινασης μεταλλακτικου εgfr | |
| PH12020550781A1 (en) | Anti-jagged1 antibodies and methods of use | |
| PH12017500877B1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
| PH12016501894B1 (en) | Anti-ox40 antibodies and methods of use | |
| PH12017500322A1 (en) | Anti-her2 antibodies and immunoconjugates | |
| MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
| MY193661A (en) | Anti-tim3 antibodies and methods of use | |
| PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
| MY188940A (en) | Anti-pd-l1 antibodies and diagnostic uses thereof | |
| MA40579A (fr) | Anticorps anti-cll-1 et immunoconjugués | |
| SG10202010155YA (en) | Compositions and methods for making antibodies based on use of expression-enhancing loci | |
| EP3154591C0 (en) | PHOSPHOLIPID COMPOSITION, AND MICROBUBLES AND EMULSIONS FORMED USING THE SAME | |
| WO2018067520A3 (en) | Therapeutic agents and methods: | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| MX2020012893A (es) | Formulaciones de proteinas. | |
| SI3523315T1 (sl) | Inhibitor glukokortikoidnega receptorja | |
| MX2016016233A (es) | Anticuerpos anti-lgr5 y sus usos. | |
| PL3113774T3 (pl) | Kompozycje grapiprantu i sposoby ich zastosowania | |
| MA39355A1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
| EP3094172A4 (en) | Animal claw shearing apparatuses and methods of using the same | |
| NZ744340A (en) | Anti-jagged1 antibodies and methods of use |